Literature DB >> 19416292

Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

K Daly1, J Koch, N Respaldiza, C de la Horra, M A Montes-Cano, F J Medrano, J M Varela, E J Calderon, P D Walzer.   

Abstract

The use of recombinant fragments of the major surface glycoprotein (Msg) of Pneumocystis jirovecii has proven useful for studying serological immune responses of blood donors and human immunodeficiency virus (HIV)-positive (HIV(+)) patients. Here, we have used ELISA to measure antibody titres to Msg fragments (MsgA, MsgB, MsgC1, MsgC3, MsgC8 and MsgC9) in sera isolated in the USA (n=200) and Spain (n=326), to determine whether geographical location affects serological responses to these antigens. Blood donors from Seville exhibited a significantly greater antibody titre to MsgC8, and significantly lower responses to MsgC3 and MsgC9, than did Cincinnati (USA) donors. Spanish blood donors (n=162) also exhibited elevated responses to MsgC1, MsgC8 and MsgC9 as compared with Spanish HIV(+) (n=164) patients. HIV(+) patients who had Pneumocystis pneumonia (PcP(+)) exhibited a higher response to MsgC8 than did HIV(+) PcP(-) patients. These data show that geographical location plays a role in responsiveness to Msg fragments. Additionally, these fragments have utility in differentiating HIV(+) PcP and HIV(+) PcP(+) among patient populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416292      PMCID: PMC2766022          DOI: 10.1111/j.1469-0691.2009.02716.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  45 in total

1.  Residence at the expression site is necessary and sufficient for the transcription of surface antigen genes of Pneumocystis carinii.

Authors:  S M Sunkin; J R Stringer
Journal:  Mol Microbiol       Date:  1997-07       Impact factor: 3.501

2.  CD4+ T cell-independent vaccination against Pneumocystis carinii in mice.

Authors:  M Zheng; J E Shellito; L Marrero; Q Zhong; S Julian; P Ye; V Wallace; P Schwarzenberger; J K Kolls
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

3.  Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants.

Authors:  S L Vargas; W T Hughes; M E Santolaya; A V Ulloa; C A Ponce; C E Cabrera; F Cumsille; F Gigliotti
Journal:  Clin Infect Dis       Date:  2001-03-09       Impact factor: 9.079

Review 4.  Pneumocystis carinii.

Authors:  Ann E Wakefield
Journal:  Br Med Bull       Date:  2002       Impact factor: 4.291

5.  Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds.

Authors:  M S Dworkin; D L Hanson; J E Kaplan; J L Jones; J W Ward
Journal:  J Infect Dis       Date:  2000-07-14       Impact factor: 5.226

6.  Pneumocystis carinii host origin defines the antibody specificity and protective response induced by immunization.

Authors:  F Gigliotti; A G Harmsen
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

7.  Characterization of the expression site of the major surface glycoprotein of human-derived Pneumocystis carinii.

Authors:  G Kutty; L Ma; J A Kovacs
Journal:  Mol Microbiol       Date:  2001-10       Impact factor: 3.501

8.  Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Constantine G Haidaris; Terry W Wright; Allen G Harmsen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

9.  Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients.

Authors:  Lisa R Bishop; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2003-05-29       Impact factor: 5.226

10.  Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons.

Authors:  Kieran R Daly; Carl J Fichtenbaum; Reiko Tanaka; Michael J Linke; Robert O'Bert; Timothy D Thullen; Michele S Hui; Alan G Smulian; Peter D Walzer
Journal:  J Infect Dis       Date:  2002-08-09       Impact factor: 5.226

View more
  13 in total

1.  Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.

Authors:  Kpandja Djawe; Kieran R Daly; Sergio L Vargas; M Elena Santolaya; Carolina A Ponce; Rebeca Bustamante; Judith Koch; Linda Levin; Peter D Walzer
Journal:  Int J Infect Dis       Date:  2010-12       Impact factor: 3.623

Review 2.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 3.  Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches.

Authors:  Marjorie Bateman; Rita Oladele; Jay K Kolls
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

Review 4.  The ecology of pneumocystis: perspectives, personal recollections, and future research opportunities.

Authors:  Peter D Walzer
Journal:  J Eukaryot Microbiol       Date:  2013-09-03       Impact factor: 3.346

5.  Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers.

Authors:  Kristina Crothers; Kieran R Daly; David Rimland; Matthew Bidwell Goetz; Cynthia L Gibert; Adeel A Butt; Amy C Justice; Kpandja Djawe; Linda Levin; Peter D Walzer
Journal:  Clin Vaccine Immunol       Date:  2010-12-29

6.  Evidence for high prevalence of Pneumocystis jirovecii exposure among Cameroonians.

Authors:  Stephenson W Nkinin; Kieran R Daly; Peter D Walzer; Edward S Ndzi; Tazoacha Asonganyi; Nieves Respaldiza; Francisco J Medrano; Edna S Kaneshiro
Journal:  Acta Trop       Date:  2009-08-07       Impact factor: 3.112

Review 7.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

8.  Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Authors:  Kpandja Djawe; Laurence Huang; Kieran R Daly; Linda Levin; Judy Koch; Alexandra Schwartzman; Serena Fong; Brenna Roth; Anuradha Subramanian; Katherine Grieco; Leah Jarlsberg; Peter D Walzer
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

9.  Humoral immune responses to Pneumocystis jirovecii antigens in HIV-infected and uninfected young children with pneumocystis pneumonia.

Authors:  Kpandja Djawe; Kieran R Daly; Linda Levin; Heather J Zar; Peter D Walzer
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

10.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.